Skip to main content

Table 2 Adverse events according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0

From: Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer

ToxicityAll gradesGrade 3 or higher
Hematologic
 Anemia101(97.1%)18(17.3%)
 Neutropenia69(66.3%)44(42.3%)
 Leukopenia69(66.3%)25(24.0%)
 Thrombocytopenia73(70.2%)2(1.9%)
Nonhematologic
 Febrile neutropenia  6(5.8%)
 Anorexia43(41.3%)1(1.0%)
 Fatigue89(85.6%)0(0.0%)
 Stomatitis32(30.8%)0(0.0%)
 Diarrhea63(60.6%)3(2.9%)
 Constipation50(48.1%)0(0.0%)
 Nausea71(68.3%)0(0.0%)
 PN93(89.4%)11(10.6%)
 Edema in limbs29(27.9%)0(0.0%)
  1. PN peripheral sensory neuropathy